Pre-warning Risk Scoring System for Sudden Cardiac Death
Key facts
- Who runs it
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 100,000 people, planned
- Started
- 2 Mar 2023
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Record updated
- 5 June 2024
Who can take part
- Age
- 16 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- The subjects with the following diagnosis of one or more cardiovascular diseases:
- Coronary heart disease If there is a history of coronary heart disease or a new diagnosis of coronary heart disease, or with a report of coronary angiography that indicates at least one vascular stenosis>50%. Diagnosis includes chronic coronary syndrome (stable angina, ischemic cardiomyopathy, and occult coronary heart disease) and acute coronary syndrome (unstable angina, ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction)
- Heart failure Individuals with a history of heart failure or newly diagnosed heart failure, including heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction (LVEF) ≤40%)、intermediate heart failure (HFmrEF, LVEF 41%-49%,with evidence of spontaneous or excitable increase in left ventricular filling pressure), and ejection fraction preserving heart failure (HFpEF, LVEF≥50%, there is evidence of spontaneous or excitable increase in left ventricular filling pressure)
- Genetically related cardiomyopathy or arrhythmia Cardiomyopathy includes hypertrophic cardiomyopathy (DCM), dilated cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), inflammatory cardiomyopathy (myocarditis, sarcoidosis, Chagas disease). Hereditary arrhythmias include long QT syndrome, short QT syndrome, Brugada syndrome, idiopathic ventricular fibrillation, catecholamine sensitive polymorphic ventricular tachycardia (CPVT), early repolarization syndrome, etc
- Sign an informed consent form
Who cannot take part
- Individuals with severe mental disorders who are unable to express their wishes
- Other obvious physical diseases and abnormal laboratory test results
- Age<16 years old
- Refusal to the follow-up visits
- Patients deemed unsuitable for participation in this study by the supervising physician
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sudden cardiac death
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational study is to identify potential indicators for pre-warning of sudden cardiac death (SCD), including clinical biochemistry markers, electrocardiogram, echocardiography, MRI and CT imaging values, genetic markers and so on, and further construct a series of multi-parameter assessments of SCD early screening.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT06440083, who can take part
- Record updated
- 5 June 2024